arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BURZYNSKI RESEARCH INSTITUTE INC

BZYR
— Price unavailable
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
63 Visible periods
20 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BURZYNSKI RESEARCH INSTITUTE INC shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC 488.3% →
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-331.45K
↑ +10.7% —
FCF / Share Free cash flow per share
$-0.01
↓ -767.3% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 3329.3% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.28x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 63 quarters